group. The results show that VEGF-transfected BMSC as well as the combination of PRP and BMSC improve vascularization, but bone healing was better with the combination of BMSC and PRP than with VEGF-transfected BMSC. Expression of VEGF in BMSC as a single growth factor does not seem to be as effective for bone formation as expanded BMSC alone or PRP which contains a mixture of growth factors. 
Introduction
Healing large bone defects remains a major challenge in orthopedic surgery [Damien and Parsons, 1991; Arrington et al., 1996] . As autogenously harvested bone transplants are limited and callus distraction is not feasible in every defect site, alternative strategies involving the use of bone substitutes, bone marrow stromal cells (BMSC), and growth factors have successfully been explored [Niemeyer et al., 2009a, b; Janicki et al., 2010; Kasten et al., 2010] . It is known that vascularization is important and tightly regulated in bone healing [DePalma et al., 1972; Burchardt and Enneking, 1978] . Healing occurs in three distinct but overlapping stages: (1) the early inflammatory stage, (2) the repair stage, and (3) the late remodeling stage [Bruder et al., 1994] . In the inflammatory stage of the first weeks the ingrowth of vascular tissue takes place and improves the nutrient and oxygen supply [DePalma et al., 1972; Burchardt and Enneking, 1978] . During the repair stage, fibroblasts begin to lay down a stroma that helps support vascular ingrowth [Laurencin et al., 1999] . As vascular ingrowth progresses, a collagen matrix is laid down while osteoid is secreted and subsequently mineralized, which leads to the formation of a soft callus around the repair site [DePalma et al., 1972; Burchardt and Enneking, 1978] . Fracture healing is completed during the remodeling stage in which the healing bone is restored to its original shape, structure, and mechanical strength. During this stage a stable and sufficient vascular supply is formed.
As vascularity of the healing site is important during all stages, growth factors that improve vascularity have become increasingly popular. Vascular endothelial growth factor (VEGF), for example, has proven to increase the blood supply [Geiger et al., 2007a] . The short half-life of VEGF (6-8 h), however, is considered problematic to achieve an effective level of growth factors. Therefore, a steady level of growth factor release at the site of the bony defect by viral transfection of BMSC has been investigated in the past [Geiger et al., 2007a] . Indeed, transfection of BMSC by the mammalian expression vector phVEGF 165 which contains the cDNA for recombinant human VEGF 165 led to higher vascularization and faster resorption of the bone substitute [Geiger et al., 2007a] . Another adjunct to improve bone healing is platelet-rich plasma (PRP) [Kasten et al., 2008a; Niemeyer et al., 2010] . PRP can easily be obtained on the day of surgery by two centrifugation steps from autogenous whole blood. It contains not only VEGF but also a number of other growth factors like platelet-derived growth factor (PDGF), transforming growth factor (TGF)-␤ 1 , TGF-␤ 2 , insulin-like growth factor (IGF), epidermal growth factor (EGF), and endothelial cell growth factor (ECGF) in their natural composition [Kiuru et al., 1991; Kasten et al., 2006; Vogel et al., 2006] . A critical-size bone defect can heal if, for example, bone substitutes are inserted into the defect [Puelacher et al., 1996; Marcacci et al., 1999; Wippermann et al., 1999] . In the present study a resorbable synthetic bone substitution material called calcium-deficient hydroxyapatite (CDHA) was chosen as a scaffold whose surface area is approximately 50 m 2 /g, thus approaching the values of about 80 m 2 /g found in natural bone [Kasten et al., 2003] .
The two aforementioned concepts for improving bone healing (on one hand gene therapy with the use of transfected BMSC and on the other hand the use of a mix of natural growth factors from platelets) are completely different, and research groups often use either one or the other. The aim of this study was to compare these two concepts in terms of efficacy in one experimental setting in a critical-size bone defect of the radius in rabbits. The hypothesis was that both concepts are equally effective in improving vascularization and finally bone healing.
Material and Methods

Animals
According to the study protocol, the following groups (each n = 6) were compared: The critical-size defects of the radius were filled with: (1) a CDHA scaffold + phVEGF 165 -transfected BMSC (VEGF group), (2) CDHA and PRP, or (3) CDHA, autogenous BMSC, and PRP. As controls served: (4) the CDHA scaffold alone and (5) the CDHA scaffold and autogenous BMSC. Six-to 9-month-old female New Zealand white rabbits (NZWR) were kept in separate cages; they were fed a standard diet and allowed to move freely during the study. Animals were treated in compliance with our institution's guiding principles 'in the care and use of animals'. The local ethics committee for animal experiments approved the design of the experiment. The groups PRP + CDHA and PRP + BMSC + CDHA that were treated in parallel were used for comparison [Kasten et al., 2008b] . One animal in the CDHA + PRP group sustained a fracture of the forearm and was excluded from the study.
Ceramic Scaffolds and PRP
CDHA ceramic cylinders 15 mm in length and 4 mm in diameter [Dr. h.c. Robert Mathys Foundation (RMS) , Switzerland] were produced in an emulsion process as described earlier [Bohner, 2000; LeGeros, 2002] . They have a specific surface area that approximates 48 m 2 /g with a total porosity or 85 vol% (54% macropores and 31% micropores). As published previously, for the preparation of PRP, on average 17 ml (SD 3.67) of blood was ob-tained from the ear arteries of six anesthetized 6-month-old NZWR [Kasten et al., 2008b] . The protocol was adapted from Yamada et al. [2004] . The blood was collected in tubes that were rinsed with heparin and the platelets were counted in Neugebauer chambers. The average platelet number was 1.9 ! 10 8 /ml (SD 0.39 ! 10 8 ). Then, the blood was centrifuged twice: initially at 209 g for 16 min at 20 ° C to remove red blood cells and then at 1,500 g for 12 min at 20 ° C to obtain the platelet pellet. The cell pellet was suspended in platelet-poor plasma, resulting in an average platelet number of 10.05 ! 10 8 /ml (SD 3.2 ! 10 8 ). The PRP of the six donors was mixed and stored at -80 ° C until needed, and consequently allogenic and standardized PRP was used.
Bone Marrow Aspiration and BMSC Expansion
Bone marrow was aspirated and prepared from tibias from all rabbits about 18 days before surgery as described previously [Louisia et al., 1999] . In brief, the surgical technique was as follows: with the animal under general anesthesia, the bone marrow of the tibia was penetrated antegradely via the proximal anterior tibial metaphysis using a sterile bone marrow aspiration needle with a diameter of 3 mm. After reaching the marrow space and removing the trocar, the bone marrow was aspirated using a 2-ml syringe containing 0.1 ml heparin. The aspirated marrow was mixed in a 15-ml Falcon tube containing 5 ml of predigestion medium [0.5 ml of collagenase (1.5 mg/ml), 0.5 ml of hyaluronidase (1 mg/ ml), and 4 ml of Verfaillie medium] [Reyes et al., 2001] . Then, the marrow aspirate was homogenized with a pipette. The aspirate was subsequently left to incubate at 39 ° C while spinning at 35 rpm continuously for 8 h (RM 540; CAT, Stauffen, Germany). Once digestion had ceased, 10 ml of phosphate-buffered saline (PBS) was added, and the predigested marrow aspirate was filtered using a 40-m filter. The samples were washed in PBS (1: 2) and centrifuged for 10 min at 677 g. Subsequently, the cells were counted and afterwards plated in cell culture flasks (Easy Flask filter, Nunclon TM surface; Nunc A/S, Roskilde, Denmark) in modified expansion medium according to Verfaillie with the addition of 2% fetal calf serum (FCS) [Reyes et al., 2001] . After 24 h, nonadhesive cells were discarded and adhesive cells were washed once with PBS. Standard culturing conditions were used (37 ° C, 5% CO 2 ), and the medium was changed twice a week. At 80-90% confluence, cells were harvested with trypsin/EDTA (Biochrom, Berlin, Germany) and replated by splitting usually 1: 3 at a density of 50-60%. Cells were cultivated until passages 2-4, equaling 16-19 population doublings. The mesenchymal differentiation potential for the osteogenic, the chondrogenic, and the adipogenic lineages was demonstrated qualitatively in vitro from aliquots of the adherent cells of the bone marrow aspirate as reported previously . Therefore, the cells fulfill the criteria of mesenchymal stem/stromal cells [Reyes et al., 2001] .
Plasmid Preparation and Transfection of Rabbit BMSC
Human VEGF (GeneBank accession No. XM 004512) was integrated into the pCR3.1 plasmid (Invitrogen, Karlsruhe, Germany) as published previously [Nikol et al., 2002; Geiger et al., 2005] using the EcoRI restriction site. This resulted in a 5.6-kb vector containing the human VEGF 165 cDNA fragment, creating the plasmid phVEGF 165 . For large scale endotoxin-free plasmid DNA production of phVEGF 165 and pCR3.1, an EndoFree Plasmid Giga Kit (Qiagen, Hilden, Germany) was used according to the manufacturer's protocol. Rabbit BMSC were cultured in cell culture flasks as described above under standard conditions (37 ° C with 5% CO 2 ). For transfection, cells were seeded at 20 ! 10 3 cells/cm 2 and allowed to adhere overnight. Transfection was performed with 1 g of plasmid DNA of phVEGF 165 or empty pCR3.1 combined with 3 l of metafectene per 100.000 cells in serum-free medium. After 6 h the medium was changed to BMSC culture medium and cells were kept overnight. Transfected cells (5 ! 10 6 ) were then seeded on each scaffold.
Loading of Cells and Application of PRP
All ceramics were incubated overnight at 4 ° C in 40 M /ml fibronectin (Sigma, Taufkirchen, Germany) solution diluted in PBS to improve the adhesion of the cells and because it was found to be beneficial for bone formation . The cells to be transplanted were detached from the culture flasks by trypsin and counted. Five million cells were then resuspended in 3 ml of culture medium and transferred into a 5-ml tube. The ceramics were placed into the medium containing the cells. After 1.5 h of continuous spinning at 37 ° C (35 ! /min) to achieve a homogeneous distribution of the cells on the surface of the scaffold, the ceramics were placed into a six-well plate. The medium containing the cells was centrifuged twice at 800 g for 5 min, and the resulting cell pellet was resuspended in 70 l of culture medium and applied to the ceramics. Previous studies demonstrated that loading BMSC statically on CDHA had an efficiency of 95% [Kasten et al., 2005] . After loading of the cells, the BMSC remain in the superficial layers within a depth of 1-2 mm [Kasten et al., 2005] . As published previously, 40 ml of freshly thawed PRP was applied to the ceramics of the PRP group, and subsequently 10 l of thrombin (0.8 IU activity)-calcium chloride (1 M ) solution (1: 1) (Tissucol-duo; Baxter, Unterschleissheim, Germany) was added directly before implantation [Kasten et al., 2008b] . Animals that received PRP had no local inflammatory response, and no systemic immune responses such as fevers were noticed [Kasten et al., 2008b] .
Surgical Procedure
The animal model was adapted from Wittbjer et al. [1982] as described previously. Briefly, unilateral 15-mm critical-size defects were created in the distal radial diaphysis. The rabbits were anesthetized with an intramuscular injection of ketamine hydrochloride (50 mg/kg body weight, Hostaket ; Intervet, Tönisvorst, Germany) and xylazine (5 mg/kg body weight, Rompun ; Bayer Vital, Leverkusen, Germany). An antibiotic (netilmicin 4 mg/kg body weight, Certomycin ; Essex Pharma, Munich, Germany) was administered perioperatively. A superomedial incision of 3 cm was made over the distal radius, soft tissues were dissected, and the bone was exposed by gentle retraction of the muscles. A Hohmann retractor was placed between the ulna and radius to protect the ulna. A 15-mm segmental diaphyseal defect was created with an oscillating saw under irrigation with 0.9 vol% sterile saline solution. The periosteum was removed with the bone and 5 mm of periosteum was stripped from each side of the remaining proximal as well as distal main fragment. The defect was irrigated with sterile physiological saline solution, and the scaffold was press fitted into the defect. Muscles, fascia, and skin were separately closed over the defect with 4-0 resorbable sutures (Ethilon; Ethicon, Norderstedt, Germany). Fixation of the osteotomized radius was unnecessary because of the fibro-osseous union of ulna and radius proximal and distal to the surgical site and the press fit of the implant. Although a certain micromotion of the implant might be possible due to resorption of the scaffold, no dislocation could be found in the subsequent control radiographs. Postoperatively, 4 mg/kg body weight of carprofen was given as needed for pain. There were no differences in carprofen administration among the groups. Water and food were supplied ad libitum. After 16 weeks the animals were euthanized. Samples were excised en bloc with the surrounding soft tissues and immediately placed in paraformaldehyde 4%.
Radiographic Evaluation
Standardized anterior-posterior and lateral radiographs were taken immediately postoperatively and every 4 weeks thereafter until sacrifice after week 16 to monitor the placement of the graft and the bony integration. An ultra-high-definition film (44 kV and 2.2 mA with a constant X-ray to object-to-film distance of 171 cm) was used. No dislocation of the scaffold was noticed in this time period.
Micro-Computer Tomography
Each specimen containing the 1.5-cm segmental defect and 0.5 cm of proximal and 0.5 cm of distal cortical bone adjacent to the defect was examined with a micro-computer tomography ( -CT) system (Fanbeam Micro-CT; Stratec, Stuttgart, Germany). The microfocus of the X-ray source of the -CT system had a spot size of 7 m and a maximum voltage of 36 kV. The image matrix was 1,024 ! 1,024 pixels. The specimens were placed in a sample holder filled with water. They were oriented in such a way that the long axis of the block was parallel to the axis of the sample holder. A high-resolution protocol (slice thickness 120 m, feed 60 m, and pixel size 60 m) was applied. Depending on the length of the specimens, up to 180 slices were scanned perpendicular to the block. To determine the amount of newly formed bone tissue, the best threshold for the CDHA scaffold alone was selected visually followed by determination of the threshold for the CDHA scaffold and newly formed bone together. Furthermore, an empty cylinder of the scaffold and several bones were scanned prior to our investigation for comparison. In addition, the ranges and means of the gray levels characteristic of the CDHA scaffold and newly formed bone were determined. The CDHA scaffold showed a mean gray level of 160 8 15, while that of the newly formed bone was 60 8 15. The visually determined threshold to separate the CDHA scaffold from newly formed bone was set at 100, allowing reliable distinction between the two tissue types. Finally, -CT slices were compared with the corresponding histological slides to verify the reliability of the discrimination criteria. The digitized data were analyzed with VG Studio Max 1.2.1 software (Volume Graphics, Heidelberg, Germany), and the amount of new bone formation (newly formed bone voxels per complete tissue voxels of the initially implanted CDHA volume) was calculated. Resorption was calculated by dividing the voxels of the ceramic that was present after 16 weeks by the voxels of the mean of three CDHA cylinders that were not implanted.
Histology and Immunohistochemical Staining for Blood Vessels
After -CT analysis, the nondecalcified specimens were dehydrated in ascending grades of alcohol and embedded in Technovit (Technovit 7200 VLC; Kulzer GmbH, Wehrheim, Germany). During embedding, the positioning of the radius was standardized in an attempt to ensure that the same region was evaluated in all specimens. Then, 50-m coronal sections with the radius and ulna parallel were made using a sawing and grinding technique (Exakt Apparatebau, Hamburg, Germany). One section of each sample was stained with Giemsa and toluidineblue (Waldeck GmbH & Co., Division Chroma, Münster, Germany) and three were used for immunohistological staining of the vessels. The sections were examined using a light microscope (Axioplan 2 Imaging; Zeiss, Göttingen, Germany). The Giemsa/ toluidine-stained specimens were digitized and analyzed with the program Image J (National Institutes of Health) [Abramoff et al., 2004] . The type of tissue was identified manually, marked, and assigned to a color. In detail, the areas of newly formed bone, connective tissue, and ceramic were calculated per total bone defect area.
Endothelial cells were stained with a monoclonal mouse antihuman CD-31 antibody (Clone: JC70A; DakoCytomation, Glastrup, Denmark; dilution 1: 20) as dexcribed previously [Geiger et al., 2007b] . The sections were deacrylated in two steps with 2-methoxy ethyl acetate for 8h, incubated 3 times with XEM for 30 min, and rehydrated followed by digestion with 0.1% chymotrypsin (Sigma-Aldrich, Deisenhofen, Germany; 60 min, 37 ° C). Endogenous peroxidase was blocked by 3% hydrogen peroxide for 30 min and nonspecific background was blocked using 5% BSA/PBS (30 min). Because the CD-31 antibody is specific for endothelial cells, vessels were stained with a monoclonal mouse anti-human CD-31 antibody (Clone: JC70A; DakoCytomation; dilution 1: 20) overnight at 4 ° C. Primary antibody was detected with the CSA biotin-free tyramide signal amplification system (DakoCytomation) according to the manufacturer's instructions. Incubation with secondary antibody, anti-mouse-immunoglobulin-HRP, amplification reagent, and anti-fluorescein-HRP lasted 30 min each and incubation with DAB chromogen took 15 min. Counterstaining was avoided due to possible influencing of the computerbased image evaluation.
On each slide, six standardized regions of interest with an area of 0.6 mm 2 were photographed at a ! 10 magnification with the Axioplan 2 (Carl-Zeiss, Oberkochen, Germany). Slices were randomly selected before staining by a blinded investigator, and blood vessels were marked by two independent examiners blinded for groups and treatment. The number of vessels in each region of interest was determined with the help of the Axiovision 4.4 program (Carl-Zeiss). The mean values of the two observers for each parameter were calculated.
Statistics
Data analysis was performed with SPSS for Windows 15.0 (SPSS, Inc., Chicago, Ill., USA). Mean values and standard deviations were calculated. The main outcome measures were newly formed bone and ceramic resorption in -CT and vessel formation in histology. These were examined by multifactorial analysis of variance (ANOVA). Differences between the independent variables were checked in post hoc tests [Tukey's studentized range (HSD) tests for variables]. The alpha error was consequently adjusted. p ! 0.05 was considered statistically significant. All tests were two-tailed.
Results
Bone Formation in -CT and Histology
Transfection of the BMSC with VEGF did not lead to a significant increase in bone formation as compared to CDHA controls ( fig. 1 ; table 1 ). This was in contrast to the groups with PRP and BMSC that showed significantly higher (p ! 0.05) bone formation than the control CDHA group ( fig. 1 ). In detail -CT analysis showed higher bone formation in the PRP group, with 24.8% of total CDHA cylinder volume (SD 5.5), and in the BMSC + PRP group (26.7%, SD 6.3), as well as in the BMSC group (22.8%, SD 6), compared to the control CDHA group without cells (11%, SD 3.6) and the VEGF group (11.3%, SD 2) (p ! 0.05). Analysis of the histology specimen showed that novel bone formation was mainly at the edges of the scaffold that were in close contact with the osteotomy surface of the radius ( fig. 2 ) . Obviously, the environment in this area is most favorable for bone formation due to direct cell contact and invasion from the adjacent bone. However, there was also bone formation within the pores of the scaffold ( fig. 2 a) . Higher magnification images were able to demonstrate direct osteoblast formation on the CDHA scaffold ( fig. 2 b) . In histology, there were no inflammatory reactions like macrophages or lymphocyte aggregations visible due to biodegradation of the scaffold.
Biodegradation of the CDHA Scaffold
Biodegradation of the scaffold was increased over the course of 16 weeks in all groups compared to the CHDA control (p ! 0.05). In the VEGF group the remaining ceramic/total ceramic volume was 64.8% (SD 3.5), in the PRP group it was 57% (SD 7.2), in the PRP + BMSC group it was 60.2% (SD 7.9), and in the CDHA + BMSC group it was 61.8% (SD 5.8) . The empty CDHA control had less biodegradation (75%, SD 8).
Vascularization in Histology
VEGF transfection of the BMSC led to higher vascularization of the scaffolds than in the BMSC and PRP fig. 3 ). Staining for CD-31 displayed the vessels within the scaffold even in deeper areas of the biomaterial ( fig. 4 a, b) .
Discussion
The hypothesis of this study was that the osteogenic capacity of VEGF-transfected BMSC on a ceramic scaffold in a critical-size long bone defect is equal to the addition of PRP and BMSC. A critical-size defect in this context means that the defect cannot heal on its own in contrast to, for example, fractures. Our data demonstrates that VEGF-transfected BMSC and the combination of PRP and BMSC are equally effective in improving vascu- This histology specimen (toluidine blue staining) from the VEGF group demonstrates bone formation at the edges of the CDHA scaffold (#) in close contact with the remaining native bone ( * ) ( a ). The lower magnification ( a ) reveals bone formation within the pores of the scaffold ( §). The higher magnification shows the direct contact of the novel bone with the scaffold (arrow) and osteoblasts (arrowhead) ( b ). c The figure shows the control of an empty CDHA scaffold that is not integrated into the bone and does not show any bony ingrowth.
larization, but bony healing was better in the combination of BMSC and PRP than with VEGF-transfected BMSC. In general, the concept of tissue engineering is based on a combination of stem cells, biomaterials, and growth factors. In the current study the same high surface scaffold CDHA was used to warrant comparison of the results. CDHA was chosen because it had shown favorable results in bone tissue engineering in the past [Kasten et al., 2005; Kasten et al., 2006; Kasten et al., 2008b] . Furthermore, bone marrow-derived stem cells (BMSC) have been shown to improve bone regeneration in comparison to the use of biomaterials alone. Consequently, the biomaterial and BMSC was determined to be the control for this study.
A critical issue in bone regeneration is a sufficient vascular supply as implantation of large bone grafts without adequate vascularity results in apoptosis and cartilage formation [Muschler et al., 2004] . This is supported by the fact that bone repair has been shown to benefit from increased angiogenesis [Santos and Reis, 2010] . The main focus of this study was to compare the effect of two ways to improve vascularization and subsequently bone regeneration. Firstly, VEGF-transfected BMSC and, secondly, a mix of growth factors derived from platelets (PRP) were used.
The growth factor VEGF has the potential to promote differentiation of common progenitor cells to angiogenic and osteogenic lineages. In embryonic development, 3 . VEGF transfection promoted vascularization of the scaffolds significantly in contrast to BMSC and PRP (p ! 0.05) but was similar to the CDHA + PRP + BMSC group. * Indicates significant differences to the empty CDHA control; * * indicates that the VEGF and PRP + BMSC groups had higher numbers of vessels than the control CDHA, the BMSC group, and the PRP group. Fig. 4 . a CD-31 staining allowed counting of the vessels within the specimen from the VEGF group. The higher magnification image shows a cut through a vessel ( * ) with staining of the endothelial cells ( b ).
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VEGFA has been considered of great importance for vascularization and patterning of the bone growth plate [Gerber et al., 1999] . VEGFA has been shown to increase bone formation in long bone defect models [Street et al., 2002; Geiger et al., 2005] , promote osteoblast differentiation in an autocrine fashion [Street et al., 2002] , inhibit osteoblast apoptosis [Street and Lenehan, 2009] , and induce endothelial cells from human embryonic stem cells [Nourse et al., 2010] . Recently, it was shown that local application of VEGFA to human adipose-derived stem cells significantly improved the healing of critical-size calvarial defects in vivo and gene activated matrices (by VEGF) improved the healing of long bone defects in rabbits [Geiger et al., 2005] . This repair was accompanied by an enhancement of angiogenesis [Behr et al., 2011] . Orchestration of bone formation is inevitably linked to a cross talk between osteoblasts and endothelial cells [Brandi and Collin-Osdoby, 2006 ]. An important mediator of angiogenesis is VEGFA [Keramaris et al., 2008] , which is physiologically released during fracture healing [Street et al., 2000] . A study demonstrated that VEGFA is primarily released by osteoblasts, whereas its action is conducted through endothelial cells [Clarkin et al., 2008] . Osteogenic effects of VEGFA on osteoblasts, such as increased bone nodule formation and alkaline phosphatase activity, have been reported in vitro [Street et al., 2002] . Moreover, VEGFA increased bone healing in vivo, whereupon delivery of VEGFA was performed with bioresorbable polylactic acid depot scaffolds or gene-activated matrices [Street et al., 2002; Geiger et al., 2005] . We are aware that the effect of a growth factor like VEGF is highly dependent on the method of administration, dosage, and other circumstances. This is why other authors found conflicting results on the effect of VEGF [Peng et al., 2002; Tarkka et al., 2003 ]. Our group has used different methods of administration in previous studies [Geiger et al., 2005 [Geiger et al., , 2007b . The way we used VEGF in this study has proven to be effective before [Geiger et al., 2007b] . As we wanted to focus on the different effects of VEGF and PRP, we did not change the experimental setting. Examination of other ways to use VEGF remains an interesting topic for future studies.
Another popular way of improving vascularization, and subsequently bone formation, is PRP. In 1998, Marx et al. [1998] reported their initial results of PRP as a source of autogenous thrombocytic growth factors for the reconstruction of maxillofacial defects in humans. They found that PRP resulted in quicker maturation of autogenous bone transplants and higher bone density [Marx et al., 1998 ]. From basic science, we know that overall platelets promote bone healing mainly by mitogenic effects, whereas the direct osteogenic effects are less pronounced [Kasten et al., 2008a] . The growth factors (PDGF, TGF, IGF, etc.) of the platelets are released after degranulation and act through a variety of pathways: the principal actions of PDGF are chemotaxis, mitogenesis, and angiogenesis and start the bone healing cascade. The PDGF effect is exerted via receptors that have tyrosine kinase activity. IL-1, TNF-␣ , and TGF-␤ 1 affect the binding of PDGF [Solheim, 1998 ]. TGF-␤ 1 is not only released by platelets but also synthesized by osteoblasts and chondrocytes throughout the healing process. TGF-␤ activates the transformation of osteoprogenitor cells into osteoblasts, which in turn initiate the production of extracellular matrix, or soft callus [Lieberman et al., 2002] . IGF-I promotes bone matrix formation (type I collagen and noncollagenous matrix proteins) by fully differentiated osteoblasts [Canalis, 1980] and is more potent than IGF-II [Lieberman et al., 2002] . IGF-II acts at a later stage of endochondral bone formation and stimulates type I collagen production, cartilage matrix synthesis, and cellular proliferation [Prisell et al., 1993] .
Besides the growth factors mentioned above, fibrin, fibronectin, and vitronectin play an important role as cell adhesions molecules. Fibronectin and vitronectin seem to be able to provide a foothold for cells as they move [Clark et al., 1982; Clark et al., 1996] . Fibrin is a crosslinked protein derived from the fibrinogen in plasma. Like fibronectin and vitronectin, it contributes to cell movement in the wound. When fibrin cross-linking occurs as part of the clotting process, it traps platelets and provides a scaffold or surface for cell movement.
Recently there have been conflicting reports about the effect of PRP plasma, and there is no consensus regarding the role of PRP in bone regeneration: there are multiple favorable results of PRP regarding the improvement of proliferation of MSC in vitro and in vivo after ectopic implantation, but also in animal models with critical-size bone defects [Kasten et al., 2008b; Bi et al., 2010; Hakimi et al., 2010; Hartmann et al., 2010; Jungbluth et al., 2010; Niemeyer et al., 2010; Bae et al., 2011; Liu et al., 2011] . However, there is also a relevant number of studies reporting no or minimal effects of PRP on bone formation [Li et al., 2004; Roldan et al., 2004; Plachokova et al., 2007; Thor et al., 2007; Vasconcelos Gurgel et al., 2007; You et al., 2007; Miloro et al., 2010; Kazakos et al., 2011] . Regarding its clinical use in maxillofacial surgery, a recent metaanalysis indicated that there was sufficient evidence to support the use of PRP for bone formation on a sinus bone graft, whereas there was no significant effect on the implant survival and bone-to-implant contact [Bae et al., 2011] . In orthopedic surgery, some authors report positive outcomes in leg lengthening procedures and spinal fusions [Bi et al., 2010; Hartmann et al., 2010] . In summary, the role of PRP remains controversial. Several studies have shown a positive effect, mainly on early bone healing, while others have not. However, most studies can hardly be compared because the study designs were very different. Factors that can influence the efficacy of PRP as a promoter of bone healing are: (1) the biomaterial, (2) the species, (3) the site of implantation, and (4) the preparation and activation of the PRP.
Rabbit thrombocytes have a survival time of 2-6 days and the growth factors are present for 1-2 days after degranulation. The platelet count in NZWR ranges from 282 ! 103/mm 3 to 1,067 ! 103/mm 3 , with an average of 563 ! 103/mm 3 in 100 normal rabbits [EBBE et al., 1965; Mitruka and Rawnley, 1977] A key question in the interpretation of this study is why bone formation of VEGF-transfected cells was inferior to the use of PRP. There are some possible explanations for this finding. Although the selective increase of the single growth factor VEGF increased vascularization in histology, this did not translate into sufficient bone formation. This can be explained by the fact that bone healing relies on a 'symphony' of different growth factors that are secreted at different time points [Street et al., 2000] . The mixture of growth factors of PRP obviously mimics nature better than a single growth factor, which might resulted in stronger bone formation after application of PRP. Another explanation could be that plasmid transfection alters the BMSC in a way that reduces bone formation. Maybe the transfection inhibits transcription programs that are necessary for proper functioning and differentiation of the BMSC in bone healing. Similar phenomena were reported after transfection of BMSC with growth differentiation factor-5 (GDF-5) for tendon regeneration [Rickert et al., 2005] .
Conclusion
Expression of VEGF in BMSC as a single growth factor does not seem to be as effective as expanded BMSC alone or PRP for healing of a critical-size long bone defect in rabbits. The mixture of growth factors in PRP seems to be more useful for bone formation than the overexpression of a single growth factor that mainly increases vascularization.
